Polymorphism of MTHFR 677CC linked with Coronary Artery Disease (CAD), says a newly published study
July 26th, 2018
A newly published Indian study of Tantray et al. investigated the role of genetic polymorphism of methylenetetrahydrofolate reductase (MTHFR) as a potential genetic marker associated with Coronary Artery Disease (CAD).
CAD due to atherosclerosis is associated with increased mortality and morbidity. India is seeing a rapid increase of people with CAD and it has been predicted that the country will host more than half of the cases of heart disease in the world within the next 15 years.
The author observed that the presence of the MTHFR C677T was significantly associated with CAD, and the percentage was greater with other common risk factors such as age, sex, diabetes mellitus, hypertension, smoking in CAD patients than in the normal subjects. MTHFR enzyme plays a crucial role in the metabolism of folates and irreversibly converts folates to 5- methyltetrahydrofolate (5-MTHF), the predominant circulatory and biologically active form of folate.
Lorena Carboni, Product Support Specialist of Gnosis, commented: “The role of this polymorphism in health and longevity is increasingly evident. Quatrefolic®, the glucosamine salt of the 5-MTHF, is already the active folate form and bypasses the polymorphism of MTHFR. Quatrefolic® can be a great solution for a right folate supplementation, to promote longer and healthier life, also in people with CAD."
Thanks to their multiple benefits and ongoing studies to discover new applications, folates have been once again the focus of researcher’s attention!
Click the below link and read more about the study performed by Tantray et al.